Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the results of a Phase Ib study evaluating tebentafusp in combination with durvalumab and/or tremelimumab in metastatic cutaneous melanoma (NCT02535078). This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.